公司簡(jiǎn)介
深圳霧曼科技有限公司成立于2021年6月,是一家致力于霧化技術(shù)研究與應(yīng)用的高科技企業(yè)。公司創(chuàng)始人及核心技術(shù)團(tuán)隊(duì)來自清華、南開、上海交大及華為系,與清華大學(xué)、中科院、深圳農(nóng)業(yè)科技促進(jìn)中心建立戰(zhàn)略合作,深入研究前沿霧化新技術(shù)和新材料,把新技術(shù)應(yīng)用到各個(gè)霧化行業(yè)。目前擁有多項(xiàng)國(guó)家發(fā)明專利、9項(xiàng)實(shí)用新型專利、8項(xiàng)外觀專利。企業(yè)聚焦現(xiàn)代農(nóng)業(yè)(大棚種植、禽畜養(yǎng)殖)、醫(yī)療健康、碳中和等幾大行業(yè),為他們提供霧化芯、霧化模組、霧化應(yīng)用產(chǎn)品、霧化助劑和霧化解決方案。
公司全球首創(chuàng)寄生霧化專利,應(yīng)用寄生霧化技術(shù)形成氣溶膠,低溫霧化功能性液體并使其長(zhǎng)期懸浮彌散全空間,從而不影響藥效且長(zhǎng)時(shí)間無死角地發(fā)揮各類液體功能。產(chǎn)品適用于現(xiàn)在市面上大部分農(nóng)藥、葉面肥、益生菌、生物酶、消毒液、除醛芳香液體。在現(xiàn)代農(nóng)業(yè)中,解決了人力耗費(fèi)、農(nóng)藥中毒風(fēng)險(xiǎn)、滅殺效率低且不徹底、耗水量大造成水害等行業(yè)痛點(diǎn),綜合成本下降一個(gè)數(shù)量級(jí)。
公司主要產(chǎn)品霧曼WM-Y-360系列全空間消殺機(jī)消殺效果經(jīng)過國(guó)家權(quán)威機(jī)構(gòu)檢測(cè)消殺效果>99.99%。目前該產(chǎn)品廣泛應(yīng)用在多個(gè)省市農(nóng)業(yè)大棚滅殺病蟲害、養(yǎng)雞場(chǎng)等養(yǎng)殖業(yè)滅殺病菌、治療呼吸道疾病等場(chǎng)合,顯著的效果深受客戶歡迎。
Shenzhen Wooman Technology Co. Ltd
Company Profile
Founded in June 2021, Shenzhen Wooman Technology Co. Ltd. is a high-tech enterprise dedicated to the research and application of atomization technology. The company conducts in-depth research on cutting-edge new technologies and materials for atomization.
* A number of national invention patents have been applied for, and the world's first parasitic atomization technology has significant advantages. The superlattice heating atomization technology obviously optimizes the metal heating atomization technology.
* Focus on modern agriculture (greenhouse planting, livestock breeding), medical health, carbon neutrality and other major industries, providing with atomization cores, atomization modules, atomization application products, atomization auxiliaries and atomization solutions.
* The trial production used for agricultural greenhouse planting and livestock breeding, was completed in the fourth quarter of 2022, with remarkable results, will be fully rolled out in 2023!
*The electronic heating atomizer using traditional Chinese medicine essential oil formula by Taiwan Professor Chen Bingkun, just passed the FDA test in February of 2023, for the treatment of respiratory diseases.